Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued ...
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, ...
Brian J. Snyder, MD, FAANS, an attending neurosurgeon and partner at Neurological Surgery, P.C. (NSPC) was the first surgeon in New York State to implant the next generation Nevro Senza II Spinal Cord ...
Nevro ($NVRO) scored a victory in its patent battle against Boston Scientific ($BSX) over high-frequency spinal cord modulation technology, as the U.S. Patent and ...
First Quarter 2023 Worldwide Revenue of $96.3 Million Grew 10% As Reported and 11% Constant Currency Compared to First Quarter 2022 Painful Diabetic Neuropathy (PDN) Indication Sales of Approximately ...
Nevro, a chronic pain medical device company, today announced the acquisition of Vyrsa Technology, a company focused on minimally invasive treatments for patients with chronic sacroiliac joint (SI ...
Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results